← Back to Screener
Praxis Precision Medicines, Inc. Common Stock (PRAX)
Price$342.57
Favorite Metrics
Price vs S&P 500 (26W)534.32%
Price vs S&P 500 (4W)5.32%
Market Capitalization$9.54B
All Metrics
Book Value / Share (Quarterly)$34.85
P/TBV (Annual)1.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.89
Price vs S&P 500 (YTD)12.07%
Net Profit Margin (TTM)-2137.48%
EPS (TTM)$-13.45
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$-13.45
EPS (Annual)$-13.48
ROI (Annual)-34.54%
Cash / Share (Quarterly)$23.79
ROA (Last FY)-32.33%
EBITD / Share (TTM)$-14.49
ROE (5Y Avg)-120.08%
Operating Margin (TTM)-2340.29%
Cash Flow / Share (Annual)$-9.89
P/B Ratio10.86x
P/B Ratio (Quarterly)8.39x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)1073.49x
Net Interest Coverage (TTM)-659.00x
ROA (TTM)-53.54%
EPS Incl Extra (Annual)$-13.48
Current Ratio (Annual)10.22x
Quick Ratio (Quarterly)10.03x
3-Month Avg Trading Volume0.52M
52-Week Price Return1048.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.67
P/S Ratio (Annual)1115.27x
Asset Turnover (Annual)0.02x
52-Week High$356.00
EPS Excl Extra (Annual)$-13.48
26-Week Price Return543.07%
Quick Ratio (Annual)10.03x
13-Week Price Return14.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.22x
Enterprise Value$9,181.581
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)35.94%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2137.48%
Cash / Share (Annual)$23.79
3-Month Return Std Dev60.79%
Net Income / Employee (TTM)$-2
ROE (Last FY)-34.54%
EPS Basic Excl Extra (Annual)$-13.48
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-13.45
ROI (TTM)-58.74%
P/S Ratio (TTM)1115.27x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.54
Price vs S&P 500 (52W)1013.27%
Year-to-Date Return16.20%
5-Day Price Return8.04%
EPS Normalized (Annual)$-13.48
ROA (5Y Avg)-90.67%
Net Profit Margin (Annual)-2137.48%
Month-to-Date Return6.30%
Cash Flow / Share (TTM)$-1.79
EBITD / Share (Annual)$-14.49
Operating Margin (Annual)-2340.29%
ROI (5Y Avg)-120.08%
EPS Basic Excl Extra (TTM)$-13.45
P/TBV (Quarterly)1.75x
P/B Ratio (Annual)8.39x
Pretax Margin (TTM)-2137.48%
Book Value / Share (Annual)$34.85
Price vs S&P 500 (13W)11.89%
Beta2.91x
Revenue / Share (TTM)$0.00
ROE (TTM)-58.74%
52-Week Low$28.79
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.13
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRAXPraxis Precision Medicines, Inc. Common Stock | 1115.27x | — | — | — | $342.57 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company leverages two proprietary platforms, Cerebrum and Solidus, to advance a portfolio of four clinical-stage candidates targeting movement disorders and epilepsy, including Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen.